Among the drugs employed for CRC therapy are the monoclonal antibodies cetuximab (Cxm) and panitumumab, which specifically target and inactivate the signaling of ERBB1, which is the EGF receptor. This evidence concerns the gene EGFR and colorectal carcinoma.